Keeping in line with its strategy to launch its prostate
cancer test by the first half of 2013,
Genomic Health, Inc.
) set a presentation at the American Urological Association
("AUA"), scheduled on May 8, 2013. Here the company will
demonstrate complete results from the positive clinical
validation study of its biopsy-based Oncotype DX prostate cancer
The company stated that the presentation will include the
results of previously conducted development studies led by
Cleveland Clinic based on 700 patients and 700 candidate genes,
which were needed to select the required genes for this test. The
company is currently making efforts to launch this Oncotype DX
Genomic Prostate Score (GPS) by the end of the second quarter of
We note that, earlier in September, the company announced
positive results from a large clinical validation study of GPS.
The study, which was performed in collaboration with prostate
cancer researchers of the University of California, demonstrated
that the multi-gene OncotypeDX GPS assessed in prostate needle
biopsy tumor tissue is a predictor of adverse pathology for
patients with early-stage prostate cancer. The study supported
the results of six earlier feasibility and development studies
performed in collaboration with the Cleveland Clinic.
We believe that with the commercial launch, GPS will create a
sizable impact on the market as prostate cancer is among the most
common types of cancers. According to the 2012 data, 900,000
people worldwide were diagnosed with prostate cancer and based
upon the results of prostate-specific antigen (PSA) testing,
biopsies were performed on over one million men in the U.S., out
of which 240,000 were diagnosed with prostate cancer.
As a global cancer company, Genomic Health is focused on the
development and commercialization of genomic-based clinical tests
for cancer diagnosis that enables physicians to make customized
treatment decisions. The company strongly believes that the
launch of the prostate cancer test will further strengthen its
advanced next generation sequencing (NGS) platform and accelerate
the development of the future tests.
Genomic Health carries a Zacks Rank #3 (Hold). Other medical
device stocks worth a look are
Medical Action Industries Inc.
). All the stocks carry a Zacks Rank #1 (Strong Buy).
CYTOKINETCS INC (CYTK): Free Stock Analysis
GENOMIC HEALTH (GHDX): Free Stock Analysis
GIVEN IMAGING (GIVN): Free Stock Analysis
MEDICAL ACTION (MDCI): Free Stock Analysis
To read this article on Zacks.com click here.